ID
15543
Beskrivning
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Please document clinically significant findings as Adverse Events. Clinical Significance is defined as any variation in physical findings that has medical relevance and may result in an alteration in medical care. Safety Blood and Urine Examinations: Please document the results for Serum Creatinine, Platelets and TSH on CRF-Pages "Safety Laboratory Assessments". Part: Relapse Evaluation Visit No. 2
Länk
https://clinicaltrials.gov/ct2/show/NCT02419378
Nyckelord
Versioner (1)
- 2016-06-02 2016-06-02 -
Uppladdad den
2 juni 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
C0449438 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0278454 (UMLS CUI [1,2])
C0022417 (UMLS CUI [1,3])
C0022417 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,2])
C1705848 (UMLS CUI [1,3])